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Human Cancer Biology
Genomic Loss of miR-486 Regulates Tumor Progression and the
OLFM4 Antiapoptotic Factor in Gastric Cancer
Hue-Kian Oh1, Angie Lay-Keng Tan3, Kakoli Das3, Chia-Huey Ooi3, Nian-Tao Deng3, Iain BeeHuat Tan2,
Emmanuel Beillard3, Julian Lee1, Kalpana Ramnarayanan1, Sun-Young Rha6,
Nallasivam Palanisamy4, P. Mathijs Voorhoeve3, and Patrick Tan1,3,4,5
Abstract
Purpose: MicroRNAs (miRNA) play pivotal oncogenic and tumor-suppressor roles in several human
cancers. We sought to discover novel tumor-suppressor miRNAs in gastric cancer (GC).
Experimental Design: Using Agilent miRNA microarrays, we compared miRNA expression profiles of
40 primary gastric tumors and 40 gastric normal tissues, identifyingmiRNAs significantly downregulated in
gastric tumors.
Results: Among the top 80 miRNAs differentially expressed between gastric tumors and normals (false
discovery rate < 0.01), we identified hsa-miR-486 (miR-486) as a significantly downregulated miRNA in
primary GCs and GC cell lines. Restoration of miR-486 expression in GC cell lines (YCC3, SCH and AGS)
caused suppression of several pro-oncogenic traits, whereas conversely inhibiting miR-486 expression in
YCC6 GC cells enhanced cellular proliferation. Array-CGH analysis of 106 primary GCs revealed genomic
loss of the miR-486 locus in approximately 25% to 30% of GCs, including two tumors with focal genomic
losses specifically deleting miR-486, consistent with miR-486 playing a tumor-suppressive role. Bioinfor-
matic analysis identified the secreted antiapoptotic glycoprotein OLFM4 as a potential miR-486 target.
Restoring miR-486 expression in GC cells decreased endogenous OLFM4 transcript and protein levels, and
also inhibited expression of luciferase reporters containing anOLFM4 30 untranslated regionwith predicted
miR-486 binding sites. Supporting the biological relevance of OLFM4 as a miR-486 target, proliferation in
GC cells was also significantly reduced by OLFM4 silencing.
Conclusions: miR-486 may function as a novel tumor-suppressor miRNA in GC. Its antioncogenic
activity may involve the direct targeting and inhibition ofOLFM4. Clin Cancer Res; 17(9); 2657–67.2011
AACR.
Introduction
Gastric cancer (GC) is the second leading cause of global
cancer mortality with a particularly high incidence in many
Asian countries (1). Most GC patients are diagnosed with
advanced stage disease and show extremely poor prognosis
(2). The 5-year survival rate for patients with stage II disease
ranges from 30% to 50%, falling to 10% to 25% for stage III
patients (3, 4). Disease recurrence is also common, with
less than 20% of late stage patients surviving beyond 5
years (3, 4). Despite a global decline in incidence, GC
remains a disease of outstanding morbidity and mortality.
Achieving a better understanding of recurrent molecular
aberrations associated with GC carcinogenesis might iden-
tify new diagnostic and treatment strategies for this disease.
Genetic factors implicated in GC development include
somatic mutations in classical tumor-suppressor genes and
oncogenes (p53, b-catenin), gene amplifications and dele-
tions (e.g., c-Met and ERBB2), and epigenetic inactivation
of CDKN2A (p16), CDH1 (E-cadherin), hMLH1, and
RUNX3 (5, 6). Besides protein coding genes, recent evi-
dence has shown an important role for noncoding RNAs in
human cancer and in particular microRNAs (miRNA; ref.
7). miRNAs are naturally occurring small RNAmolecules of
approximately 22 nucleotides (8) which base-pair with
complementary sequences located in the 30 untranslated
regions (UTR) of target genes, causing either target mRNA
degradation or reduced protein translation (9, 10). An
individual miRNA can regulate a large number of target
mRNAs (11), and conversely a single genemay be regulated
Authors' Affiliations: 1Cellular and Molecular Research and 2Division of
Medical Oncology, National Cancer Centre of Singapore; 3Cancer and
Stem Cell Biology, Duke-NUS Graduate Medical School; 4Genome Insti-
tute of Singapore; 5Cancer Science Institute of Singapore, Yong Loo Lin
School of Medicine, National University of Singapore, Singapore; and
6Department of Internal Medicine, Yonsei Cancer Center, Yonsei Univer-
sity College of Medicine, Seodaemun-Ku, Seoul, Korea
Note: Supplementary data for this article are available at Clinical Cancer
Research Online (http://clincancerres.aacrjournals.org/).
Current address for N. Palanisamy: Michigan Center for Translational
Pathology and Departments of Pathology, Ann Arbor, MI 48109.
Corresponding Author: Patrick Tan, Cancer andStemCell Biology, Duke-
NUSGraduateMedical School, 8CollegeRoad, Singapore 169857. Phone:
65-65161783; Fax: 65-62212402. E-mail: gmstanp@duke-nus.edu.sg
doi: 10.1158/1078-0432.CCR-10-3152
2011 American Association for Cancer Research.
Clinical
Cancer
Research
www.aacrjournals.org 2657
by multiple independent miRNAs. The ability of miRNAs
to affect multiple downstream target genes suggests that
miRNAs may be particularly adept at broadly modulating
the activity of multiple cellular pathways (9, 10). In cancer,
miRNAs can exert either oncogenic or tumor-suppressive
roles (12). Oncogenic miRNAs such as miR-21, mir-155,
mir-17–92, and miR-372/miR-373 are frequently upregu-
lated in tumors and can negatively regulate tumor-suppres-
sor genes such as Bim, PTEN, and LATS2 (12–14).
Conversely, tumor-suppressive miRNAs, which are usually
underexpressed in tumors, have been shown to inhibit
oncogenes such as RAS, BCL2, and MYC (12). Some
examples of tumor-suppressor miRNAs include let-7, mir-
15, and mir-16.
In GC, several miRNA profiling studies have been
reported (15, 16). However, most of these previous stu-
dies have largely focused on characterizing oncogenic
miRNAs (e.g., miR-21, miR-27a, and the miR106b-25
cluster; refs. 17–19). In contrast, relatively few tumor-
suppressor miRNAs in GC are known, and although
candidates such as miR-141, miR-143, miR-145, miR-9,
and miR-218 have been proposed as possible tumor-
suppressor miRNAs, their functions and target genes have
not been extensively explored (20–24). Here, we com-
pared miRNA expression profiles of gastric tumors and
matched normal tissues to identify hsa-miR-486-5p (miR-
486) as a significantly downregulated miRNA in GC.
Subsequent functional characterization revealed that
miR-486 inactivation is required for the expression of
several pro-oncogenic traits, which may involve miR-
486 targeting the OLFM4 antiapoptotic factor. Impor-
tantly, we observed frequent and focal genomic deletions
of the miR-486 locus in 20% to 30% of GCs, consistent
with miR-486 playing a tumor-suppressor role. Finally,
miR-486 downregulation has also been observed in sev-
eral other human cancers (25), it is thus possible that
miR-486 may exert important tumor-suppressive func-
tions in other cancer types besides GC.
Materials and Methods
Primary gastric cancer samples and cell lines
Primary gastric tumors and adjacent matched normal
gastric tissues were obtained from the National Cancer
Centre Singapore and the Singhealth Tissue Repository.
Primary samples were collected with signed patient
informed consent and with approval from institutional
review boards. GC cell lines AGS, Kato III, SNU1, NCI-
N87, and Hs746T were obtained from the American Type
Culture Collection (ATCC) and AZ-521, TMK1, MKN1,
MKN7, MKN45 cells were obtained from the Japanese
Collection of Research Bioresources (JCRB). SCH cells
were a gift from Yoshiaki Ito (Cancer Sciences Institute of
Singapore). YCC1, YCC3, YCC6, YCC7 cells were a gift
from Sun-Young Rha (Yonsei Cancer Center, South
Korea). All cell lines were tested and authenticated by
the respective cell line bank (ATCC, JCRB) or the origi-
nating institution (YCC) by several methods including
DNA fingerprinting and/or cytogenetics. Prior to the
commencement of this study, we independently re-
authenticated the cell lines by comparing their gen-
ome-wide copy number (array-CGH) and mutational
profiles to the published literature.
miRNA expression profiling
Total RNA was extracted from primary tissues and cell
lines by using the miRVana miRNA Isolation Kit (Ambion,
Inc.) according to the manufacturer’s instructions. RNA
samples were hybridized to Agilent Human miRNA Micro-
arrays (V2) representing 723 human and 76 human viral
miRNAs, and scanned using an Agilent DNA Microarray
Scanner (Model G2565BA). miRNA expression values were
normalized against background signals by Feature Extrac-
tion Software (Agilent). The miRNA data were also sub-
jected to a log 10 transformation followed by median
centering across probes, prior to in-depth analysis.
The miRNA expression data have been deposited into
GEO under accession number GSE23739.
Microarray data analysis
Differentially expressedmiRNAs were identified by using
the significance analysis of microarrays (SAM) program in
BRB-ArrayTools (http://linus.nci.nih.gov/brb/tool.htm),
using a false discovery rate (FDR) cutoff of less than 0.01.
Significance of Pearson correlations (R) between 2 N-ele-
ment vectors were estimated from the Student t distribu-
tion, against the null hypothesis that the observed value of t
¼ R/ ﬃp [(1  R2)/(N  2)] arises from a population in
which the true correlation coefficient is zero. Of 146
differentially expressed miRNAs initially identified by
SAM (FDR < 0.01), we focused on the top 40 miRNAs
exhibiting the highest positive log fold change (most
Translational Relevance
Gastric cancer (GC) is the second leading cause of
global cancer mortality. In this study, we carried out
microRNA (miRNA) profiling of primary GCs and cell
lines to identify hsa-miR-486-5p (miR-486) as a signifi-
cantly downregulated miRNA in GC. Subsequent func-
tional characterization revealed that miR-486
inactivation is required for the expression of several
pro-oncogenic traits, and that this is likely mediated
through miR-486 targeting the OLFM4 antiapoptotic
factor. miR-486 is located at Chr 8p11, a region of
frequent genomic loss in multiple cancers. Consistent
with miR-486 playing a tumor-suppressor role, we
observed by array-CGH frequent genomic deletion of
miR-486 in 20% to 30% of GCs. miR-486 may thus
represent a novel tumor-suppressor miRNAs in GC
inactivated through genomic deletion. By understand-
ing the mechanism and function of miR-486 as a tumor
suppressor, it may be possible to develop miR-486 as a
diagnostic or therapeutic agent in GC treatment.
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upregulated) and the top 40 miRNAs with the lowest
negative log fold change (most downregulated). Among
the 40 most significant downregulated miRNAs in tumors,
we triaged 16 candidate tumor-suppressor miRNAs meet-
ing the additional criterion of detectible expression in an
independent normal stomach sample from a healthy
patient (Stratagene), at levels greater than the median
expression in GC cell lines.
Real-time quantitative reverse transcriptase PCR
Quantitative reverse transcriptase PCR (qRT-PCR) was
carried out by using an ABI7900HT Fast real-time PCR
system (Applied Biosystems). TaqMan Universal PCR Mas-
ter Mix (Applied Biosystems), TaqMan Reverse Transcrip-
tion Kit, and TaqMan MicroRNA Assay kits (Applied
Biosystems) were used to measure miR-486 expression
levels according to the manufacturer’s instructions. Each
PCR was normalized against an RNU6B internal control.
All PCR reactions were done in triplicate.
Additional methods
Detailed methods on miR-486 expression and silencing,
OLFM4 silencing and overexpression, cell proliferation and
anchorage-independent growth assays, cell migration and
invasion assays, array-CGH assays and copy number ana-
lysis, miRNA target prediction, Western blotting, OLFM4
30-UTR Luciferase Reporter Assays, and in situ hybridization
are reported in the Supplementary Data.
Results
Identification of differentially regulated microRNAs
in primary gastric tumors
To identify miRNAs exhibiting expression changes in GC,
we profiled 40 gastric tumors and 40 noncancerous gastric
tissues on Agilent miRNA microarrays measuring approxi-
mately 800 miRNAs (723 human and 76 viral miRNAs).
Gastric tumors are traditionally classified by histology into 2
major groups-–intestinal (expanding or differentiated) and
diffuse (infiltrative or undifferentiated; ref. 26). Our analysis
covered both GC subtypes, because half of the tumors were
intestinal-type GC (20 samples), whereas the other half were
diffuse-type cancers. An initial unsupervised analysis where
the gastric samples were clustered by using miRNAs detect-
ibly expressed in 25% or more of the samples (329 probes)
resulted in an overall partitioning of gastric tumors away
from normals, indicating the existence of pervasive miRNA
expression differences between the 2 groups (Supplementary
Fig. S1). We focused our analysis on miRNAs exhibiting
striking differences in expression between gastric normals
and tumors. Using SAM, we identified 80miRNAs that were
significantly differentially expressed between the 2 groups
(FDR < 0.01; Fig. 1A; Supplementary Table S1 provides a list
of the top 80 miRNAs).
We divided the differentially regulated miRNAs into 3
distinct classes on the basis of their global expression
patterns. The first class of miRNAs exhibited high expres-
sion in tumors relative to normals—these may represent
potential pro-oncogenic miRNAs contributing to GC
development and progression. Supporting this idea,
among the most highly expressed miRNAs in this class
were miR-21, miR-27a, and miR-17—3 miRNAs that have
been functionally confirmed to exert oncogenic functions
Figure 1.Global identification of differentially expressed miRNAs between
gastric normal tissues and tumors. A, identification of differentially
expressed miRNAs. Top, expression heat map showing expression of 80
differentially expressed miRNAs between and 40 normal gastric tissues
(gray bar) and 40 GCs (blue and yellow bars; FDR < 0.01, using SAM, see
Materials and Methods). Bottom, differential expression of miRNAs
between intestinal-type and diffuse-type GCs (Int-GC and Diff-GC,
respectively) analyzed from a separate SAM run (FDR < 0.01). B, heat map
showing differential expression of 16 candidate tumor-suppressor
miRNAs. Expression of miR-486 is highlighted in red type.
miR-486 as a Tumor Suppressor in Gastric Cancer
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in multiple cancer types including GC (17, 18). The
reidentification of these known oncogenic miRNAs sup-
ports the biological validity of the miRNA microarray
data. Interestingly, we also observed upregulation of hsa-
miR-16 and hsa-miR-214 in GC—2 miRNAs that have
been previously reported to be downregulated in prostate
and cervical cancers (27, 28). It is thus possible that
certain miRNAs may exert either pro or antioncogenic
functions that are dependent on tissue type.
The second class comprised miRNAs exhibiting down-
regulation in tumors relative to normals—such miRNAs
might represent candidates for potential tumor-suppressor
miRNAs. Given the relative lack of validated tumor-sup-
pressor miRNAs in GC compared with oncogenic miRNAs,
we decided to focus on this list for further analysis. Using
multiple filtering criteria (see Materials and Methods), we
nominated a set of 16 candidate tumor-suppressor miRNAs
(Fig. 1B). Providing confidence in our filtering criteria,
among the 16 candidates we reidentifiedmir-375, a known
tumor-suppressor miRNA in GC (29). These miRNAs are
further considered in the next section.
We also detected a third and smaller class of miRNAs that
were differentially expressed between intestinal and dif-
fuse-type GCs (Fig. 1A, bottom). In general, these miRNAs
(hsa-let7d*, hsa-miR-328, hsa-miR-32*, hsa-miR-1227, hsa-
miR-206, hsa-miR-1229, hsa-miR-595, and hsa-miR-631)
were largely downregulated in diffuse-type GCs compared
with intestinal-type GCs. Although not the primary focus
on this study, these results raise the possibility that differ-
ences in miRNA expression may also exist between the 2
major histologic subtypes of GC.
Expression patterns of miR-486, a candidate tumor-
suppressor miRNA in GC
Hypothesizing that some of the 16 nominated miRNAs
exhibitingdecreased expression inGCmight represent bona
fide GC tumor suppressors, we selected a handful for func-
tional validation.Here,we report our findings for the first of
these candidates, hsa-miR-486–5p, hereafter referred to as
miR-486. miR-486 is located on chromosome 8p11 within
intron41of theAnkyrin-1 (ANK1) gene (Fig. 2A).miR-486 is
transcribed from an alternative promoter within intron 40
Figure 2. Expression of candidate tumor-suppressor hsa-miR-486-5p in gastric tumors and cell lines. A, genomic location of miR-486. miR-486 is located
on chromosome 8p11 within the ANK1 gene, between exons 41 and 42.miR-486 is transcribed from the same strand from an alternative promoter located in
intron 40 of the ANK1 gene. B, reciprocal expression of miR-486 compared with 3 previously reported oncogenic miRNAs (mir-17, mir-21, and mir-27a)
across gastric normal tissues and GCs. C, quantitative PCR (qPCR) analysis showing relative expression ofmiR-486 in 29 primary GC tissues compared with
matched adjacent normal tissues. Quantifications were measured by TaqMan real-time PCR. Each column represents an individual tumor/normal pair.
Fold changes (tumor/normal) were transformed to log 2 values (y-axis). P values denotes the significance of fold change observed. D, expression ofmiR-486
and mir-17 in primary gastric tissues (normals and tumors) and GC cell lines. The x-axis depicts primary GCs (first column, n ¼ 40, median), 15 GC cell
lines, and primary normal gastric tissues (blue arrow and box, last column, n¼ 40, median). Expression ofmiR-486 is in green whereasmir-17 is in pink (color
legend). Error bars indicate respective standard deviations across tumors or normals. R denotes the Pearson correlation between the 2 miRNAs. P values
denoting the significance of the correlation coefficient R. Cell lines selected for functional analysis are highlighted in red (YCC3, AGS, SCH, YCC6).
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of the ANK1 gene (30), and has been previously shown to
regulate phosphoinositide3-kinase signaling inmuscle cells
by targeting the PTEN gene (30). In contrast to its role in
muscle development, the role of miR-486 in epithelial
tumorigenesis is currently unclear.
Three observations suggest that miR-486 may play a
potential tumor-suppressive role in GC. First, besides exhi-
biting reduced expression in tumors compared with the
normal tissues, miR-486 is expressed in a strikingly reci-
procal pattern to the oncogenic miRNAs miR-17, miR-21,
and miR-27a (Fig. 2B, bottom). Second, to validate the
microarray results, we carried out qRT-PCR to directly
measure miR-486 expression levels in a cohort of 28 pri-
mary GC tissues and matched adjacent normal tissues.
Eighty percent of the tumors expressed decreased levels
of miR-486 expression by at least 2-fold compared with
matched normal tissues, confirming that miR-486 is
expressed at significantly lower levels in GCs (P < 0.05,
paired t test; Fig. 2C). In situ hybridization experiments on
fixed gastric tissue sections confirmed miR-486 expression
in normal gastric epithelial cells, but reduced or absent
expression in gastric tumors (Supplementary Fig. S2).
Third, to further validate the reduced expression of miR-
486 in GC cells, we investigated miR-486 expression in a
panel of 15 GC cell lines. Similar to the primary tumors, 14
of 15 GC cell lines underexpressed miR-486 while simul-
taneously overexpressing the mir-17 oncogenic miRNA (P
¼ 0.001; Fig. 2D). Taken collectively, these results suggest
that miR-486 may play a tumor-suppressive role in GC.
miR-486 expression inhibits proliferation, anchorage-
independent growth, migration, and invasion in GC
cells
To investigate the functional significance of miR-486
downregulation in GC, we selected 3 GC cell lines
(YCC3, AGS, and SCH) for further studies as these 3 lines
express low levels of miR-486 (Fig. 2D). Synthetic miR-486
precursor molecules were transfected into these cells lines
to restore miR-486 expression, and restoration of miR-486
expression in these cells was confirmed by qRT-PCR
(Fig. 3A). First, we compared the cell proliferation rates
of control and miR-486 transfected cells at various time
points. In all 3 cell lines, the growth ofmiR-486 transfected
cells was significantly reduced compared with cells trans-
fected with negative-control miRNAs (Fig. 3B). This result
suggests that restoring miR-486 expression is sufficient to
inhibit cellular proliferation in GC.
Second, to examine the importance of miR-486 in the
tumorigenesis of GC cells, we carried out anchorage-inde-
pendent growth assays. Using a blasticidin selection pro-
tocol (see Materials and Methods), we generated stable
pools of SCH, YCC3, and AGS cells expressing miR-486 or
empty vector controls. SCH and YCC3 cells transfected with
empty vector controls grew well in soft agar, forming
distinct colonies (Fig. 3C). In contrast, SCH and YCC3
cells expressing miR-486 exhibited a dramatic reduction in
the number of soft agar colonies (Fig. 3C), showing trans-
forming abilities less than 50% of the control cells. Similar
data were obtained for AGS cells (Fig. 3C, right). These
results suggest that miR-486 can suppress the tumorigene-
city of GC cells in vitro.
Third, to assess the effect of miR-486 in GC migration
and invasion, we tested AGS cells stably expressingmiR-486
or empty vectors. AGS cells expressing vector controls
migrated robustly in Transwell assays (Fig. 3D, top),
whereas AGS cells overexpressing miR-486 exhibited a
significant reduction in migration capacity (P < 0.05,
approximately 2-fold). Similarly, in invasion assays, AGS
cells overexpressing miR-486 exhibited a 2-fold reduced
capacity for invasion compared with controls (P ¼ 0.05;
Fig. 3D, bottom).
Fourth, of the 15 GC cell lines tested in this study, we
identified 1 line (YCC6) expressing above-average levels of
miR-486 (Fig. 2D). To investigate the cellular effects of
silencing rather than overexpressing miR-486, we inhibited
endogenousmiR-486 expression in YCC6 cells by transfect-
ing the cells with miR-486 inhibitors (anti–miR-486). Effi-
cient inhibition of miR-486 expression was confirmed by
qRT-PCR (Fig. 3E). miR-486–suppressed YCC6 cells exhib-
ited a modest but significant enhancement of cell prolif-
eration compared with control transfected cells (P < 0.05;
Fig. 3E). Taken collectively, these results indicate that
restoring miR-486 expression is sufficient to suppress sev-
eral pro-oncogenic traits in vitro, whereas conversely sup-
pressing miR-486 expression is sufficient to enhance such
traits, consistent withmiR-486 playing a tumor-suppressive
role in GC.
Frequent genomic loss of miR-486 in GC
A preliminary transcriptomic analysis of GC cell lines
treated with inhibitors of DNA methyltransferase or his-
tone deactylation inhibitors failed to provide evidence of
epigenetic silencing of miR-486 in GC (data not shown).
Besides epigenetic silencing (31), genomic loss is another
mechanism by which tumor-suppressor miRNAs can be
downregulated in cancer (32). Notably, miR-486 is located
on chromosome 8p11, a frequent region of loss of hetero-
zygosity in many cancers, including GC (33, 34). Although
ANK1, the gene within which miR-486 lies, has been
proposed as a potential tumor-suppressor gene in this
region (34, 35), there is in reality very little functional
evidence supporting an antioncogenic role for ANK1. These
findings raise the possibility that other genetic elements on
8p11 lying close to ANK1, such as miR-486, may represent
important driver elements for the frequent genomic losses
associated with this region in cancer.
To investigate whether miR-486 might be genomically
deleted inGC,weanalyzedan in-house array-CGHdatabase
of 106 gastric tumors profiled on Agilent 244Kmicroarrays.
Strikingly, we obtained genomic loss of the miR-486 locus
within a window of 500 kb on chromosome 8 in 25% to
30% of GCs (Fig. 4A). In individual GCs, the size of the
genomic deletion ranged from 100 to 300 kb. Moreover,
arguing against the possibility of another nearby gene driv-
ing these deletions, 2 tumors (GC990187 and GC200088)
exhibited highly focal genomic regions specifically deleting
miR-486 as a Tumor Suppressor in Gastric Cancer
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Figure 3. miR-486 expression modulates multiple pro-oncogenic traits. A, restoration of miR-486 expression in GC cell lines. YCC3, SCH, and AGS cells
were transfected with control (Ctr) or miR-486 precursors, qRT-PCR was carried out to assess relative miR-486 expression. B, miR-486 expression
suppresses cellular proliferation in GC cell lines. miR-486–transfected cell lines were assessed for cell proliferation at 24, 48, and 72 hours posttransfection.
Triplicate experiments were conducted for each set. *, P < 0.05, t test; points, mean; bars, SD. C, miR-486 expression suppresses anchorage-independent
cell growth. Left, soft-agar colony formation assay reduction showing reduced in colony numbers in SCH and YCC3 stably transfected with miR-486 or
empty vector control. Right, the quantification of colonies observed. Triplicate experiments were conducted for each cell lines. Columns, mean; bars, SD;
*, P < 0.05, t test. D, miR-486 reduces motility and invasiveness of AGS cells. Top, migration of AGS cells stably expressing miR-486 or vector controls,
measured by a Transwell migration assay. Columns, mean; bars, SD; *, P < 0.05. Bottom, invasion of AGS cells stably expressing miR-486 or vector
controls, measured by a Matrigel assay. Insert, phase contrast microscopy of the crystal-violet stained cells in Matrigel. Columns, mean; bars, SD;
**, P ¼ 0.059. E, inhibition ofmiR-486 expression promotes cellular proliferation in YCC6. Top,miR-486 inhibitor and negative control inhibitor [anti–miR-486
(red) and anti–miR-ctr (blue)] transfected cells were assessed for miR-486 expression by qRT-PCR. Bottom, cell proliferation levels were assayed at
24 and 48 hours posttransfection. Triplicate experiments were conducted for each set. Points, mean; bars, SD; significance for the difference in growth
denoted by *, P < 0.05.
Oh et al.
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the miR-486 locus [GC990187—chr8:41,582,276-
41,727,172 (135 kb); GC200088—chr8:41,582,276-
41,717,096 (145 kb); Fig. 4B and C], whereas retaining a
portion of the ANK1 gene. We also observed a genomic
deletion at themiR-486 region in the GC cell line SCH (data
not shown). These results indicate that the miR-486 geno-
mic locus is frequently deleted in GCs, supporting the
notion that miR-486 is a tumor-suppressor miRNA.
The antiapoptotic factor OLFM4 is a direct miR-486
target
To better understand the mechanisms underlying the
tumor-suppressive capacities of miR-486, we searched for
candidate miR-486 target genes with potential pro-onco-
genic functions. Using 2miRNA target prediction programs
(TargetScan 5.1 and miRanda v3.0), we identified 17
candidate miR-486 target genes commonly predicted by
both programs (Fig. 5A). Among these 17 genes, 2 (TOB1
and ARID1A) have been previously shown to be associated
with tumor-suppressive functions (36, 37). More impor-
tantly, we identified SP5 and OLFM4, as potential pro-
oncogenicmiR-486 target genes (38, 39). Our attention was
specifically drawn toOLFM4 (Olfactomedin-4/GW112), as
OLFM4 has been previously reported to be highly expressed
in gastric tumors and specifically GC cells compared
with normal tissues (39–41). Both prediction programs
identified one potentialmiR-486 binding site in theOLFM4
30-UTR.
Functionally, OLFM4 has also been shown to behave as
an antiapoptotic factor and to promote tumor growth and
invasion (see Discussion; refs. 42, 43). Confirming pre-
vious reports, we found that OLFM4 was indeed highly
expressed in GCs compared with gastric normals (P <
0.001; Fig. 5B). Also supporting recent findings, the high
expression ofOLFM4 in tumors was largely associated with
intestinal-type GCs (Table 1; ref. 40). No significant asso-
ciations were observed between OLFM4 expression with
tumor stage, grade, or patient survival (data not shown).
Figure 4. Genomic Loss of miR-
486 in primary GCs. A, recurrent
genomic loss of miR-486. Red
bars highlight the miR-486 locus.
Top, genomic location ofmiR-486
on Chr 8p11.21. Middle,
histogram showing frequency of
genomic loss in this region across
106 primary GCs. Twenty-eight
percent of GCs (30 tumors) are
observed to exhibit loss of the
miR-486 locus (blue horizontal
bars below histogram). Genomic
loss of the miR-486 locus in
individual samples. Only samples
with miR-486 loss are shown. The
color gradient depicts the extent
of copy number deletion. Bottom,
genome browser view of the Chr
8p11.21 region showing miR-486
and adjacent genes such as
ANK1. B and C, focal deletion of
miR-486 in 2 gastric tumor
samples: 2000088 and 990187.
The copy number log-ratio data
are shown together with segments
identified. ThemiR-486 locus (with
focal deletion) is highlighted in red.
miR-486 as a Tumor Suppressor in Gastric Cancer
www.aacrjournals.org Clin Cancer Res; 17(9) May 1, 2011 2663
To investigate relationships between endogenous miR-
486 andOLFM4 expression, we analyzed 11 intestinal-type
primary GCs and matched nonmalignant tissues for which
both miR-486 and OLFM4 expression were available. miR-
486 was significantly negatively correlated to OLFM4
expression (R ¼ 0.619; P ¼ 0.0031; Fig. 5C), consistent
withmiR-486 targetingOLFM4 in vivo. To directly assess the
functional impact of miR-486 on OLFM4 expression, we
transfected GC cells (YCC3 and AGS) with miR-486 pre-
cursors and measured endogenous OLFM4 expression
Figure 5. Direct regulation of Olfactomedin-4 (OLFM4) bymiR-486. A,miR-486 target prediction by miRanda v3.0 and TargetScan 5.1 algorithms. Seventeen
targets were common to both prediction programs (genes in box). OLFM4 is highlighted in red. B, OLFM4 is highly expressed in primary gastric tumors
compared with matched normal tissues (P < 0.001). C, OLFM4 andmiR-486 in intestinal-type primary GCs and matched normals. We observed a significant
negative correlation of miR-486 to OLFM4 expression (R ¼ 0.61852; P ¼ 0.003106) in 11 intestinal-type GCs and 7 matched normal tissues analyzed. D,
OLFM4 protein levels are regulated bymiR-486. Western blot analyses ofOLFM4 protein in cells transfected withmiR-486 or negative control mimics.OLFM4
protein levels ware lower in YCC3 cells expressing miR-486 as compared with control-miR–expressing cells. Similar reductions in OLFM4 protein were also
observed inmiR-486–expressing AGS cells. Quantitative real-time PCR showed thatOLFM4 transcripts are also reduced in cells transfected withmiR-486 as
compared with controls. (*, t test for OLFM4 expression in miR-486 vs. control cells). E, OLFM4 is a direct target of miR-486. The predicted miR-486 target
region found in the OLFM4 mRNA 30-UTR was cloned downstream of luciferase in a pMIR-Report-luciferase reporter vector. Reporter constructs were
cotransfected with miR-486 and negative control mimic molecules into AGS cells. Luciferase reporter assays were normalized to b-galactosidase activities
and experiments were conducted in triplicates. Data were plotted after normalized against the negative control miRNA mimics. Columns, mean; bars,
SD. F, silencing ofOLFM4 in GC cells YCC3 and SCH by siRNA reduces cell proliferation capacity. YCC3 and SCH cells were transfected with siRNAs against
OLFM4 or scrambled controls (scr, negative control). Experiments were conducted in triplicates. y-Axis denotes the absorbance at 490 nm (cell proliferation)
and x-axis is the assay time-points. Points, mean; bars, SD; significance for the difference in growth is denoted by **.
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levels. Restoration of miR-486 in YCC3 and AGS cells
caused a decrease in OLFM4 protein and transcript levels,
relative to control-transfected cells (Fig. 5D). These results
indicate that restoration ofmiR-486 in GC cells is sufficient
to suppress OLFM4 expression.
We then carried out luciferase reporter assays to show a
direct functional role of the predictedmiR-486 binding sites
in the OLFM4 30-UTR. Luciferase reporters were con-
structed containing either a wild-type OLFM4 30-UTR
sequence containing the miR-486 binding site (WT-
UTR), or a mutated OLFM4 30-UTR where the miR-486
seed sequence binding sites were altered (MUT-UTR;
Fig. 5E). The WT-UTR and MUT-UTR luciferase reporter
constructs were transfected into GC cells, along with miR-
486 or negative control miRNAs. Luciferase expression of
the WT-UTR reporter was significantly decreased compared
with MUT-UTR (P < 0.05) or vector-expressing cells in a
miR-486–dependent manner, indicating that miR-486 is
able to reduce the reporter activity of WT-UTR but not
MUT-UTR (Fig. 5E). This result strongly indicates that that
miR-486 directly targets theOLFM4 30-UTR, resulting in the
translation inhibition of OLFM4 protein.
OLFM4 expression promotes GC cell proliferation and
inhibits the antioncogenic effects of miR-486
OLFM4 has been proposed to promote tumor growth by
functioning as an antiapoptotic protein (42, 43) attenuat-
ing the apoptotic function of GRIM-19, a cell-death reg-
ulatory protein. To establish a functional role forOLFM4 in
GC, we silenced OLFM4 in YCC3 and SCH cells, and
conducted cell proliferation assays. OLFM4-silenced
YCC3 and SCH cells exhibited significantly slower cellular
proliferation compared with control siRNA-treated cells
(Fig. 5F). This result suggests that OLFM4 activity may
be required for GC development and progression. Inter-
estingly, downregulation of OLFM4 by miR-486 also
resulted in upregulation of GRIM-19, the proposed target
of OLFM4 (Supplementary Fig. S3).
Finally, to establish whether the antiproliferative effects
caused by miR-486 restoration might depend, at least in
part, on suppression of OLFM4 activity, we carried out
rescue experiments in which YCC3 cells stably expressing
miR-486 (Y4 cells) were transfected withOLFM4 expressing
constructs. We found that Y4 cells overexpressing OLFM4
exhibited a significant increase in cell proliferation com-
pared with control Y4 cells, comparable with parental
YCC3 cells (Supplementary Fig. S4). These results suggest
that the tumor-suppressive effects of miR-486 are likely to
be mediated, at least in part, through its effect on OLFM4
activity. In summary, our data suggest that miR-486 is a
tumor suppressor in GC progression and its downregula-
tion in GC by genomic deletion may facilitate tumor
growth, in part, by causing OLFM4 upregulation.
Discussion
Recent evidence has convincingly shown an important
role for miRNAs in many human cancers (7, 12). In GC,
previous miRNA profiling studies have led to the collective
identification of approximately 80 miRNAs exhibiting dys-
regulated expression between tumors and normals. How-
ever, beyond their observed expression patterns, relatively
few tumor-suppressor miRNAs have been functionally
explored in GC, notable exceptions being miR-375 (regu-
lating PDK1 and 14-3-3z) and miR-141, whose down-
stream targets are still unclear (21, 29). Thus, the true
biological relevance of many miRNAs in GC requires
further investigation. Here, we identified miR-486 as a
candidate GC tumor suppressor. Restoration of miR-486
in multiple GC cell lines significantly reduced several pro-
oncogenic traits, including cell proliferation, anchorage-
independent growth, and cell migration/invasion, whereas
silencing of miR-486 in YCC6 cells enhanced proliferation.
To our knowledge, our study is the first to functionally
explore the role of miR-486 in cancer development and
progression. However, it is worth noting that Navon and
colleagues have recently reported that miR-486 is under-
expressed in several other cancer types besides GC (25).
Thus, the tumor-suppressive role ofmiR-486 in cancer may
not be limited to GC alone and our findings may have
relevance to other cancer types.
The exact mechanisms causing miR-486 downregulation
in cancers deserve further study. In this study, we found that
approximately 25% to 30% of gastric tumors exhibited a
genomic loss of the chromosome 8p11 region where miR-
486 is located. This frequency of 8p loss is comparable with
previous array-based CGH studies of GC (44, 45). More-
over, genomic deletions inmiRNAs have been reported as a
mechanism for miRNA downregulation, as shown formiR-
101, miR-15a, and miR-16-1 (32, 46). However, because
70%ofGCs did not exhibit observable genomic loss ofmiR-
486, genomic deletions alone are unlikely to fully explain
the pervasive downregulation of miR-486 in GC. It is thus
almost certain that other GC tumors must employ alter-
native mechanisms to achieve miR-486 downregulation,
such as epigenetic silencing or transcriptional repression,
as reported formiR-124 (47) or transcriptional suppression
of the miR-29a promoter by myc (48). In our study, we did
Table 1. High OLFM4 expression is associated
with intestinal-type GC
Lauren's
classification
Intestinal Diffuse Mixed Total
OLFM4
low expression
37 42 8 87
OLFM4
high expression
52 24 11 87
Total 89 66 19 174
NOTE: A Pearson c2 statistic was used to test the associa-
tion of the expression ofOLFM4with GC histologic subtype
(174 tumors). High OLFM4 expression was positively asso-
ciated with intestinal-type GC (Pearson c2 test, P ¼ 0.019).
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not observe evidenceofmiR-486 epigenetic regulationwhen
GC cell lines were treated with either inhibitors of DNA
methyltransferase or histone acetyltransferases; however,
these experiments were far from exhaustive. More work is
thus required to fully delineate the spectrumofmechanisms
responsible for miR-486 downregulation in GC.
Our study suggests that OLFM4 is likely a direct target
gene of miR-486. However, it is likely oversimplistic to
expect that the antioncogenic effects of miR-486 can be
entirely explained by its ability to regulate a single gene
alone, particularly because previous studies investigating
the cellular functions of miRNAs have shown that a single
miRNA can often regulate many genes and gene targets
(11). Besides OLFM4, our bioinformatic analysis we iden-
tified 16 other potential miR-486 target genes, several of
which may function in cancer (e.g., FBN1, HAT1, SP5,
TOB1, ARID1A, and OLFM4), and miR-486 has also been
shown to target PTEN in muscle cells (30). Nevertheless,
OLFM4 is likely to be a biologically relevantmiR-486 target
in the context of GC. OLFM4 has been reported to be
overexpressed in various cancers including GC but also
colon, breast, and lung cancers (41), and has been pro-
posed as a potential serum biomarker of GC (39). Func-
tionally, OLFM4 has been shown to interact with GRIM19
(a cell-death regulatory protein), cadherins, and lectins,
and OLFM4 has been shown to inhibit apoptosis and
promote tumor growth and invasion (41–43). However,
a recent finding showed that OLFM4 has a proapoptotic
effect in myeloid leukemia cells (49). In our study, the
biological relevance of OLFM4 as a miR-486 target was
supported by showing thatOLFM4 silencing can reduce GC
cellular proliferation, and that OLFM4 overexpression can
rescue the antioncogenic effects of miR-486. Interestingly,
despite miR-486 being downregulated in both intestinal
and diffuse-type GCs, we found that OLFM4 overexpres-
sion was largely confined to intestinal-type GCs. It is
possible that in diffuse-type GCs OLFM4might be targeted
by additional miRNAs and not simplymiR-486. Consistent
with this notion, preliminary bioinformatic analysis sug-
gests that the OLFM4 gene may be targeted by more than
400 different miRNAs (data not shown). Thus, other miR-
NAs may also act to target OLFM4 in diffuse-type GCs,
whereas in intestinal-type GCs, miR-486 regulation of
OLFM4 may exert a predominant role. In this regard, it
is intriguing to note that OLFM4 has also been recently
reported to be a robust marker of intestinal stem cells (50).
In conclusion, our data suggest thatmiR-486may act as a
novel tumor-suppressor miRNA in GC, and that its down-
regulation in gastric tumors may be required for GC devel-
opment and progression. Besides providing insights in
basic aspects of GC biology, our findings may also have
translational relevance as miRNAs have also been proposed
to represent potential therapeutic candidates. By under-
standing the mechanism and function of miR-486 as a
tumor suppressor, it may be eventually possible to develop
miR-486 as a therapeutic agent in GC treatment.
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